Pediatrix Medical Group MD Purchased finite-lived intangible assets

Other financials

Revenue$476.2M+3.9%

Operating income$41.7M+29.8%

Net income$29.6M+42.6%

EPS (diluted)$0.36+50.0%

Cash & equivalents$205.8M+108%

Total debt$629.7M-3.9%

Total equity$878.6M+11.3%

Total assets$2.1B+3.9%

Operating cash flow-$129.8M-10.5%

CapEx$6.2M+88.3%

Free cash flow-$136.1M-12.7%

Market cap$1.99B+42.9%

Enterprise value$2.41B+22.3%

P/E11.4×—

P/S1×+0.3×

Operating margin11.3%—

Net margin9%—

FCF margin12.3%+2.5pp

Return on equity20.9%—

Debt / equity0.7×-0.1×

Current ratio1.3×-0.5×

Reported directly by Pediatrix Medical Group in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles.

The official record: Pediatrix Medical Group’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Pediatrix Medical Group's purchased finite-lived intangible assets?: Pediatrix Medical Group (MD) reported purchased finite-lived intangible assets of $400K in Q1 2026.